» Articles » PMID: 24272804

Peptides and Proteins As Drugs

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2013 Nov 26
PMID 24272804
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Relatively small modifications of clinically useful endogenous compounds have been shown to have therapeutically beneficial effects on their pharmacodynamic and pharmacokinetic properties. These effects include increased potency and effect selectivity, and prolonged duration of action. In addition, these modifications have resulted in compounds that can be administered orally where only parenteral administration was previously possible. One type of modification resulting in distinctive properties is exemplified by the hybrid interferons produced by the recombination of segments of genes coding for different molecular species. Chemical modification has also resulted in many examples of analogs of natural peptides that are more potent, more selective and more stable than the endogenous compounds. Conjugation to peptide or protein carriers is a third method used to selectively modify the properties of an endogenous compound. The carriers that have been used include synthetic polypeptides, endogenous proteins, toxins and monoclonal antibodies. The effect that covalent attachment to a carrier has on the properties of a ligand is highly dependent upon the carrier, the ligand and the linkage between them.

Citing Articles

Oral absorption of peptides: influence of pH and inhibitors on the intestinal hydrolysis of leu-enkephalin and analogues.

Friedman D, Amidon G Pharm Res. 1991; 8(1):93-6.

PMID: 2014216 DOI: 10.1023/a:1015842609565.


A comparison of peptidase activities and peptide metabolism in cultured mouse keratinocytes and neonatal mouse epidermis.

Shah P, Borchardt R Pharm Res. 1991; 8(1):70-5.

PMID: 2014210 DOI: 10.1023/a:1015882323677.


Transport of thyrotropin releasing hormone in rabbit buccal mucosa in vitro.

Dowty M, Knuth K, Irons B, Robinson J Pharm Res. 1992; 9(9):1113-22.

PMID: 1409390 DOI: 10.1023/a:1015883217858.

References
1.
Beverley P . Antibodies and cancer therapy. Nature. 1982; 297(5865):358-9. DOI: 10.1038/297358a0. View

2.
Vallera D, Quinones R, Azemove S, Soderling C . Monoclonal antibody-toxin conjugates reactive against human T lymphocytes. A comparison of antibody linked to intact ricin toxin with antibody linked to ricin A chain. Transplantation. 1984; 37(4):387-92. DOI: 10.1097/00007890-198404000-00015. View

3.
Verlander M, Jacobson K, Rosenkranz R, Melmon K, Goodman M . Some novel approaches to the design and synthesis of peptide-catecholamine conjugates. Biopolymers. 1983; 22(1):531-45. DOI: 10.1002/bip.360220166. View

4.
Roth R, Maddux B, Wong K, Iwamoto Y, Goldfine I . Insulin-ricin B chain conjugate. A hybrid molecule with ricin-binding activity and insulin biological activity. J Biol Chem. 1981; 256(11):5350-4. View

5.
Miskimins W, Shimizu N . Synthesis of a cytotoxic insulin cross-linked to diphtheria toxin fragment A capable of recognizing insulin receptors. Biochem Biophys Res Commun. 1979; 91(1):143-51. DOI: 10.1016/0006-291x(79)90595-3. View